<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id>
      <journal-title-group>
        <journal-title>BMC Research Notes</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-0500</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25899913</article-id>
      <article-id pub-id-type="pmc">4415237</article-id>
      <article-id pub-id-type="publisher-id">1126</article-id>
      <article-id pub-id-type="doi">10.1186/s13104-015-1126-8</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Fukuizumi</surname>
            <given-names>Aya</given-names>
          </name>
          <address>
            <email>ayafujita@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miyanaga</surname>
            <given-names>Akihiko</given-names>
          </name>
          <address>
            <email>a-miyanaga@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Seike</surname>
            <given-names>Masahiro</given-names>
          </name>
          <address>
            <email>mseike@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kato</surname>
            <given-names>Yasuhiro</given-names>
          </name>
          <address>
            <email>y-kato@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakamichi</surname>
            <given-names>Shinji</given-names>
          </name>
          <address>
            <email>snakamichi@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chubachi</surname>
            <given-names>Kumi</given-names>
          </name>
          <address>
            <email>s9048@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsumoto</surname>
            <given-names>Masaru</given-names>
          </name>
          <address>
            <email>s7062@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Noro</surname>
            <given-names>Rintaro</given-names>
          </name>
          <address>
            <email>r-noro@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Minegishi</surname>
            <given-names>Yuji</given-names>
          </name>
          <address>
            <email>yminegis@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kunugi</surname>
            <given-names>Shinobu</given-names>
          </name>
          <address>
            <email>s-hemmi@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kubota</surname>
            <given-names>Kaoru</given-names>
          </name>
          <address>
            <email>kkubota@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gemma</surname>
            <given-names>Akihiko</given-names>
          </name>
          <address>
            <email>agemma@nms.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602 Japan </aff>
        <aff id="Aff2"><label/>Department of Analytic Human Pathology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>4</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>23</day>
        <month>4</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>8</volume>
      <elocation-id>165</elocation-id>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>3</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>4</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Fukuizumi et al.; licensee BioMed Central. 2015</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Non-small-cell lung cancers (NSCLCs) harboring translocations in anaplastic lymphoma kinase (<italic>ALK</italic>) are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We describe a case of post-operative local recurrence of lung adenocarcinoma in an 81&#xA0;year-old male. He underwent radiation and received chemotherapy with docetaxel, but neither treatment regimen was effective. Following identification of ALK rearrangements, crizotinib treatment was initiated. After treatment with crizotinib for 5&#xA0;days, adverse events including acute renal failure (grade 2/CTCAE ver4.0) and congestive heart failure (grade 3) occurred. Crizotinib modified treatment was required. Half dose of crizotinib treatment could not control tumor progression. Ultimately, crizotinib was administrated at a dose of 250&#xA0;mg twice daily every 3&#xA0;day dosing for 13&#xA0;months with maintenance of the anti-tumor effect.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>This is the first case report that skip schedule was more effective than dose reduction daily in crizotinib administration for ALK rearranged NSCLC patient with severe adverse events.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>EML4&#x2013;ALK</kwd>
        <kwd>Crizotinib</kwd>
        <kwd>Non-small-cell lung cancer</kwd>
        <kwd>Congestive heart failure</kwd>
        <kwd>Schedule</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>EML4-ALK (echinoderm microtubule-associated protein-like 4 and the anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non-small-cell lung cancer (NSCLC) [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>]. Approximately 2-7% of patients with NSCLC have rearrangements in the ALK gene, leading to an oncogene-addicted state from aberrant ALK activation [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR3">3</xref>]. Preclinical and clinical studies have shown that cancer cells harboring EML4-ALK are highly sensitive to ALK inhibition [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p>Crizotinib is the first clinically available ALK tyrosine kinase inhibitor (TKI) and competes with ATP for binding to the tyrosine kinase pocket of the enzyme, inhibiting tyrosine phosphorylation of activated ALK at nanomolar concentrations. The most common adverse events associated with crizotinib include visual disturbances, gastrointestinal symptoms, peripheral edema, fatigue, decreased appetite, and elevated aminotransferases [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR6">6</xref>]. The majority of the toxicities are grade 1 or 2, and some improve with continuation of therapy. Here, we present for the first time a case in which every 3&#xA0;day dosing administration of crizotinib was effective and prevented adverse events in elderly NSCLC harboring the ALK fusion gene.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 81&#xA0;year-old male former-smoker who experienced previously acute myocardial infarction presented in January 2013 with mediastinal lymph node metastasis. He was diagnosed as lung adenocarcinoma (AC) seven years ago and underwent right-middle lobectomy and lymph node-dissection (ND2a-1). His pathological stage was stage IA (pT1bN0M0). The histopathological subtype of the specimen was mixed papillary and acinar subtype AC components (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>A). Immunohistochemistry showed positive TTF-1, PE10, CD7, and Alcian blue &amp; PAS staining. In 2011, however, a fluorine 18-labled fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET-CT) scan showed mediastinal lymph node metastasis. Although local recurrent mediastinal radiation therapy (52&#xA0;Gy) was performed, the mediastinal lymph metastasis progressed. Therefore, in January 2013 the patient received one cycle of chemotherapy with docetaxel in consideration of elderly and the co-morbities. However, the treatment was withdrawn because of serious upper gastrointestinal bleeding due to the development of hemorrhagic gastric ulcer during his medical course.<fig id="Fig1"><label>Figure 1</label><caption><p>Histological and immunohistochemical findings in the primary tumor: <bold>(A)</bold> adenocarcinoma with mixed papillary and acinar subtype (hematoxylin and eosin 40&#xD7; magnification), <bold>(B)</bold> Immunohistochemical analysis of the ALK protein expression in the tumor cells, <bold>(C)</bold> Fluorescence in situ hybridization (FISH) analysis of <italic>EML4-ALK.</italic>
</p></caption><graphic xlink:href="13104_2015_1126_Fig1_HTML" id="MO1"/></fig></p>
      <p>Mutation analysis revealed that the tumor expressed the wild type epidermal growth factor receptor (<italic>EGFR</italic>) gene. However, <italic>ALK</italic> rearrangements were identified using fluorescent in situ hybridization (FISH) and confirmed by immunohistochemistry for ALK expression in both tumors (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>B and C). Performance status (PS) was good (PS 1). We assessed that cytotoxic chemotherapy was high risk because of short time from his recovery from the upper gastrointestinal bleeding. Therefore, crizotinib was administered orally at a dose of 250&#xA0;mg twice daily as a second-line treatment (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>A and B). After 5&#xA0;days of crizotinib therapy, the patient developed acutely deteriorating dyspnea and exhibited arterial oxygen desaturation and hypoxemia (SpO2 89% in room air). Chest radiograph and CT scan revealed increase of right pleural effusions (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>C and D). Serum B-type natriuretic peptide (BNP) was increased from 134 to 314&#xA0;pg/ml (Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>), and creatinine (Cr) was elevated from 1.18 to 1.55&#xA0;mg/dl. The electrocardiogram was normal, showing no evidence of arrhythmia, or acute myocardial infarction. Increased levels of high sensitive Trop-T (0.024&#xA0;ng/ml) and CK-Mb (&lt;4.0&#xA0;ng/ml) were not found. Cardiac ultrasonography revealed no abnormality (Ejection Fraction 78%). According to the Framingham Study, we diagnosed his clinical manifestation, congestive heart failure and acute renal failure. Since side effects of crizotinib were suspected, the drug was immediately discontinued and started with furosemide 10&#xA0;mg/day. Oxygenation, serum creatinine and BNP immediately improved (Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). Therefore, crizotinib administration was resumed at 250&#xA0;mg/day combined with furosemide 10&#xA0;mg/day.<fig id="Fig2"><label>Figure 2</label><caption><p>Chest radiograph and chest CT scan before <bold>(A</bold> and <bold>B)</bold> and after <bold>(C</bold>, <bold>D</bold>, <bold>E</bold>, <bold>F</bold> and <bold>G)</bold> crizotinib treatment: <bold>(A)</bold> Chest radiograph before crizotinib therapy, <bold>(B)</bold> and swelling of the mediastinal lymph node (#4R), <bold>(C)</bold> chest radiograph after 5&#xA0;days of crizotinib treatment revealing increase in pleural effusions, <bold>(D)</bold> detection of right pleural effusions due to the appearance of congestive heart failure and renal failure, <bold>(E)</bold> disappearance of pleural effusions and significant shrinking of the mediastinal lymph node. <bold>(F)</bold> CT scan just before the crizotinib re-challenge after 4&#xA0;months withdrawal. <bold>(G)</bold> CT scan after 3&#xA0;months of the crizotinib re-challenging treatment.</p></caption><graphic xlink:href="13104_2015_1126_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Figure 3</label><caption><p>Changes in serum CEA and BNP levels after the resumption of firstly crizotinib therapy.</p></caption><graphic xlink:href="13104_2015_1126_Fig3_HTML" id="MO3"/></fig></p>
      <p>Since there were no adverse events for 10&#xA0;days, the crizotinib dose was increased to 250&#xA0;mg twice daily. By following this regimen, the patient achieved significant tumor response, as shown by CT scan (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>E). However, he complained of chest discomfort again after 3&#xA0;days and crizotinib therapy was once again discontinued. One month later, the patient was re-challenged at a low dose of 200&#xA0;mg/day crizotinib therapy. Despite the dose reduction, pleural effusion and exacerbation of creatinine (1.96&#xA0;mg/dl) and BNP (274.7&#xA0;pg/ml) occurred on day 11. Four months later, as he had increased pleural effusion and lymph node metastasis (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>F), he was re-challenged with 250&#xA0;mg/day crizotinib administered every 3&#xA0;days; however, Carcinoembryonic antigen (CEA) was elevated (Figure&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Once again 250&#xA0;mg/day drug was prescribed, but no anti-tumor effect was observed. Administration of 250&#xA0;mg twice daily was then tried on every other day, but BNP levels increased (Figure&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Finally, the frequency was reduced to 250&#xA0;mg twice daily every 3&#xA0;day dosing, and both BNP and CEA levels were decresed (Figure&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Finally, a significant response was achieved without adverse effects (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>G). This treatment has been continued with good response for 13&#xA0;months.<fig id="Fig4"><label>Figure 4</label><caption><p>Changes in serum CEA and BNP levels after the rechallenge of crizotinib therapy.</p></caption><graphic xlink:href="13104_2015_1126_Fig4_HTML" id="MO4"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>We report a rare case in which acute renal failure and congestive heart failure occurred after the administration of crizotinib for lung AC with <italic>ALK</italic> rearrangement, and in which dose and schedule modification were required. Because elevations in serum BNP, Cr and pleural effusions were reversible on discontinuation of crizotinib, these were recognized as adverse effects of crizotinib. To our knowledge, no adverse effects on congestive heart failure patients have been described with crizotinib therapy in previous clinical trials [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR6">6</xref>]. Renal toxicity of crizotinib has previously been described (&lt;10%) [<xref ref-type="bibr" rid="CR7">7</xref>]. However, the patient concerned was elderly and had exhibited a decline in cardiac function following an occurrence of acute myocardial infarction 10&#xA0;years ago. By repetition of capacity modulation, we have demonstrated the effectiveness of continuing crizotinib therapy at a dose of 250&#xA0;mg twice daily every 3&#xA0;day dosing.</p>
      <p>In EGFR-TKI treatment for advanced NSCLC with EGFR mutation, some patients need a dose reduction of gefitinib due to occurrence of several adverse effects. A treatment strategy minimizing toxicity is especially required for patients in poor condition, or for elderly patients. A previous report demonstrated that low-dose gefitinib may not be inferior to standard-dose gefitinib for NSCLC patients with <italic>EGFR</italic> mutations [<xref ref-type="bibr" rid="CR8">8</xref>]. On the other hand, there are no reports of NSCLC patients with <italic>ALK</italic> in whom successful clinical benefit without adverse effects was observed by administration of crizotinib on alternate days. Regarding a treatment schedule for crizotinib, a previous case reported progression of brain metastases under the use of standard crizotinib therapy (250&#xA0;mg twice daily); however, readjustment of crizotinib dose to 500&#xA0;mg once daily generated a favorable response [<xref ref-type="bibr" rid="CR9">9</xref>]. These authors hypothesized that increasing the maximum plasma concentration (Cmax) without increasing the daily dose of 500&#xA0;mg could be beneficial.</p>
      <p>Regarding pharmacokinetic-pharmacodynamic (PKPD) simulation of crizotinib treatment, while Cmax was 243&#xA0;ng/ml for a once daily dose of crizotinib 400&#xA0;mg, it was 493&#xA0;ng/ml for a standard schedule of 250&#xA0;mg twice daily [<xref ref-type="bibr" rid="CR10">10</xref>]. Taking into account the fact that the plasma half-life was 29.1&#xA0;hours for crizotinib 400&#xA0;mg once daily, an effective plasma concentration was preserved, since every 3&#xA0;day dosing administration of 250&#xA0;mg twice daily may have prevented excessive elevation of Cmax.</p>
    </sec>
    <sec id="Sec4" sec-type="conclusion">
      <title>Conclusions</title>
      <p>The present report indicates that alternate day administration of crizotinib is a choice worth considering, since it maintains sufficient clinical effects, while avoiding serious adverse events, especially in elderly and high-risk cases. Every 3&#xA0;day dosing administration may be an option but only in patients intolerant of standard dosing trial.</p>
      <p>Therefore, it is necessary to study the relationship between pharmacokinetics of crizotinib with every 3&#xA0;day dosing administration and clinical effects, as well as standard administration.</p>
      <sec id="Sec5">
        <title>Ethics approval and consent</title>
        <p>Clinical assessment and genetic testing in this patient were performed primarily for diagnostic purposes. The patient gave his informed consent to diagnostic genetic testing. Written informed consent was obtained from the patient&#x2019;s family for publication of this case report and accompanying images due to the death of the patient himself before publication.</p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>NSCLC</term>
          <def>
            <p>Non-small-cell lung cancer</p>
          </def>
        </def-item>
        <def-item>
          <term>EML4</term>
          <def>
            <p>Echinoderm microtubule-associated protein-like 4</p>
          </def>
        </def-item>
        <def-item>
          <term>ALK</term>
          <def>
            <p>Anaplastic lymphoma kinase</p>
          </def>
        </def-item>
        <def-item>
          <term>TKI</term>
          <def>
            <p>Tyrosine kinase inhibitor</p>
          </def>
        </def-item>
        <def-item>
          <term>AC</term>
          <def>
            <p>Adenocarcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>PET-CT</term>
          <def>
            <p>Positron emission tomography-computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>EGFR</term>
          <def>
            <p>Epidermal growth factor receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>FISH</term>
          <def>
            <p>fluorescent in situ hybridization</p>
          </def>
        </def-item>
        <def-item>
          <term>PS</term>
          <def>
            <p>Performance status</p>
          </def>
        </def-item>
        <def-item>
          <term>BNP</term>
          <def>
            <p>B-type natriuretic peptide</p>
          </def>
        </def-item>
        <def-item>
          <term>Cr</term>
          <def>
            <p>Creatinine</p>
          </def>
        </def-item>
        <def-item>
          <term>CEA</term>
          <def>
            <p>Carcinoembryonic antigen</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>AF and AM prepared the manuscript and the literature search; MS reviewed and edited the manuscript; AG corrected and revised the manuscript; YK, SN, KC and MM treated and observed the patient; SK performed the histopathological, immunohistochemical examinations; and RN, YM and KK reviewed the manuscript. All authors read and approved of the final manuscript.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Enomoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takada</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamashita</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</article-title>
          <source>Nature</source>
          <year>2007</year>
          <volume>448</volume>
          <fpage>561</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1038/nature05945</pub-id>
          <pub-id pub-id-type="pmid">17625570</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takada</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Enomoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ueno</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A mouse model for EML4-ALK-positive lung cancer</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2008</year>
          <volume>105</volume>
          <fpage>19893</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0805381105</pub-id>
          <pub-id pub-id-type="pmid">19064915</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Yeap</surname>
              <given-names>BY</given-names>
            </name>
            <name>
              <surname>Mino-Kenudson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Digumarthy</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Heist</surname>
              <given-names>RS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>4247</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2009.22.6993</pub-id>
          <pub-id pub-id-type="pmid">19667264</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwak</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Bang</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Camidge</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Maki</surname>
              <given-names>RG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</article-title>
          <source>N Engl J Med</source>
          <year>2010</year>
          <volume>363</volume>
          <fpage>1693</fpage>
          <lpage>703</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1006448</pub-id>
          <pub-id pub-id-type="pmid">20979469</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Yeap</surname>
              <given-names>BY</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Riely</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Gainor</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Engelman</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis</article-title>
          <source>Lancet Oncol</source>
          <year>2011</year>
          <volume>12</volume>
          <fpage>1004</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(11)70232-7</pub-id>
          <pub-id pub-id-type="pmid">21933749</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Camidge</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Bang</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Kwak</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Iafrate</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Varella-Garcia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>SB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study</article-title>
          <source>Lancet Oncol</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>1011</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(12)70344-3</pub-id>
          <pub-id pub-id-type="pmid">22954507</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gastaud</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ambrosetti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marquette</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Coutts</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hofman</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma</article-title>
          <source>Lung Cancer</source>
          <year>2013</year>
          <volume>82</volume>
          <fpage>362</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1016/j.lungcan.2013.08.007</pub-id>
          <pub-id pub-id-type="pmid">24001942</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Satoh</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maemondo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oizumi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Isobe</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations</article-title>
          <source>J Thorac Oncol</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>1413</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0b013e31821d43a8</pub-id>
          <pub-id pub-id-type="pmid">21681118</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peled</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Zach</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Liran</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ilouze</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bunn</surname>
              <given-names>PA</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Hirsch</surname>
              <given-names>FR</given-names>
            </name>
          </person-group>
          <article-title>Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer</article-title>
          <source>J Thorac Oncol</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>e112</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0000000000000038</pub-id>
          <pub-id pub-id-type="pmid">24389447</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="other">FDA. Xalkori Clinical Pharmacology and Biopharmaceutical Review(s) (<ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf</ext-link>). 2011.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
